ST2 Biomarker Panels for NASH Detection and Progression Monitoring
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD) are inadequate in accurately distinguishing between benign steatosis and NASH, and in monitoring the progression from benign steatosis to NASH, lacking reliable biomarkers for early detection and prognosis.
Innovation Solution
A method involving the determination of suppression levels of ST2 receptor and optionally other biomarkers such as IL-6, IL-8, TNFα, and P3NP in ex vivo blood, serum, or plasma samples, with statistical analysis to establish significance compared to controls, using a solid-state device for simultaneous biomarker detection, and employing decision trees for classification.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current diagnostic methods are used for NASH/NAFLD, then the diagnostic process is simple, but the accuracy of distinguishing between benign steatosis and NASH is inadequate
Solution Approach 1:
The patent combines multiple biomarker assessments (ST2, IL-6, IL-8, TNFα, P3NP) into a single diagnostic approach. This merging of multiple measurement targets allows differentiation between benign steatosis and NASH with higher accuracy than single-marker methods, resolving the contradiction between diagnostic precision and method complexity by integrating markers into a unified panel.
Solution Approach 2:
The diagnostic method serves multiple functions: it distinguishes benign steatosis from NASH, monitors disease progression, and provides prognostic information. This multi-functionality allows a single comprehensive approach to address multiple diagnostic needs simultaneously, improving overall diagnostic accuracy without requiring separate specialized tests for each function.
2Reliability
If current diagnostic methods are used, then the monitoring process is simple, but the ability to monitor progression from benign steatosis to NASH is inadequate
Solution Approach 1:
The patent combines multiple biomarker assessments (ST2, IL-6, IL-8, TNFα, P3NP) into a single diagnostic approach. This merging of multiple measurement targets allows differentiation between benign steatosis and NASH with higher accuracy than single-marker methods, resolving the contradiction between diagnostic precision and method complexity by integrating markers into a unified panel.
Solution Approach 2:
The diagnostic method serves multiple functions: it distinguishes benign steatosis from NASH, monitors disease progression, and provides prognostic information. This multi-functionality allows a single comprehensive approach to address multiple diagnostic needs simultaneously, improving overall diagnostic accuracy without requiring separate specialized tests for each function.
3Measurement precision
If multiple biomarkers are determined simultaneously, then the diagnostic accuracy is improved, but the device complexity increases
Solution Approach 1:
The patent combines multiple biomarker assessments (ST2, IL-6, IL-8, TNFα, P3NP) into a single diagnostic approach. This merging of multiple measurement targets allows differentiation between benign steatosis and NASH with higher accuracy than single-marker methods, resolving the contradiction between diagnostic precision and method complexity by integrating markers into a unified panel.
Data Source
AI summary
The current invention provides biomarkers and combinations thereof for the diagnosis and prognosis of inflammatory liver disease. Methods include the biomarkers suppression of tumorigenicity 2 receptor (ST2), interleukin 6 (IL-6), interleukin 8 (IL-8), tumour necrosis factor alpha (TNFα) and Procollagen III N-terminal peptide (P3NP).